Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19 Pandemic: A Community-Based, Cluster-Randomized Trial

Abstract

Introduction There is some evidence that homeopathic treatment has been used successfully in previous epidemics, and currently some countries are testing homeoprophylaxis for the coronavirus disease 2019 (COVID-19) pandemic. There is a strong tradition of homeopathic treatment in India: therefore, we decided to compare three different homeopathic medicines against placebo in prevention of COVID-19 infections.

Methods In this double-blind, cluster-randomized, placebo-controlled, four parallel arms, community-based, clinical trial, a 20,000-person sample of the population residing in Ward Number 57 of the Tangra area, Kolkata, was randomized in a 1:1:1:1 ratio of clusters to receive one of three homeopathic medicines (Bryonia alba 30cH, Gelsemium sempervirens 30cH, Phosphorus 30cH) or identical-looking placebo, for 3 (children) or 6 (adults) days. All the participants, who were aged 5 to 75 years, received ascorbic acid (vitamin C) tablets of 500 mg, once per day for 6 days. In addition, instructions on healthy diet and general hygienic measures, including hand washing, social distancing and proper use of mask and gloves, were given to all the participants.

Results No new confirmed COVID-19 cases were diagnosed in the target population during the follow-up timeframe of 1 month—December 20, 2020 to January 19, 2021—thus making the trial inconclusive. The Phosphorus group had the least exposure to COVID-19 compared with the other groups. In comparison with placebo, the occurrence of unconfirmed COVID-19 cases was significantly less in the Phosphorus group (week 1: odds ratio [OR], 0.1; 95% confidence interval [CI], 0.06 to 0.16; week 2: OR, 0.004; 95% CI, 0.0002 to 0.06; week 3: OR, 0.007; 95% CI, 0.0004 to 0.11; week 4: OR, 0.009; 95% CI, 0.0006 to 0.14), but not in the Bryonia or Gelsemium groups.

Conclusion Overall, the trial was inconclusive. The possible effect exerted by Phosphorus necessitates further investigation.

Trial registration: CTRI/2020/11/029265.

Keywords

COVID-19 - homeopathy - placebo - prophylaxis - cluster-randomized controlled trial

• References

• 1 Alschuler L, Weil A, Horwitz R. et al. Integrative considerations during the COVID-19 pandemic. Explore (NY) 2020; 16: 354-356
• 2 Seifert G, Jeitler M, Stange R. et al. The relevance of complementary and integrative medicine in the covid-19 pandemic: a qualitative review of the literature. Front Med (Lausanne) 2020; 7: 587749
• 3 Shankar A, Dubey A, Saini D, Prasad CP. Role of complementary and alternative medicine in prevention and treatment of COVID-19: an overhyped hope. Chin J Integr Med 2020; 26: 565-567
• 4 Portella CFS, Ghelman R, Abdala CVM, Schveitzer MC. Evidence map on the contributions of traditional, complementary and integrative medicines for health care in times of COVID-19. Integr Med Res 2020; 9: 100473
• 5 Das A, Ahmed R, Akhtar S, Begum K, Banu S. An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. Gene Rep 2021; 23: 101122
• 6 Chaudhary A, Khurana A. A review on the role of homoeopathy in epidemics with some reflections on COVID-19 (SARS-CoV-2). Indian J Res Homoeopathy 2020; 14: 100-109
• 7 Ministry of AYUSH, Govt. of India. Guidelines for homoeopathy practitioners for prophylaxis and symptomatic management of COVID-19 participants in home isolation. Accessed May 22, 2021
• 8 Bhapkar V, Sawant T, Bhalerao S. A critical analysis of CTRI registered AYUSH studies for COVID-19. J Ayurveda Integr Med 2020; (e-pub ahead of print)
• 9 Rao MVV, Juneja A, Maulik M. et al. Emerging trends from COVID-19 research registered in the Clinical Trials Registry—India. Indian J Med Res 2021; 153: 26-63
• 10 Varanasi R, Nayak D, Khurana A. Clinical repurposing of medicines is intrinsic to homeopathy: research initiatives on COVID-19 in India. Homeopathy 2021; 110: 198-205
• 11 Delgado JP, Garcia AE, Pla EA. et al. Large-scale homoeoprophylaxis as an add-on measure to prevent COVID-19 disease: Cuban preliminary experiences. Indian J Res Homoeopathy 2020; 14: 293-294
• 12 Fujino FMSDC, Olandim AACC, Lemonica R. et al. Antimonium tartaricum as a possible homeopathic prophylactic remedy in the COVID-19 epidemic. Homeopathy 2021; 110: 206-211
• 13 Vaishampayan S, Mutreja K, Lambe S, Shah J, Shaikh G. Mercurius solubilis as genus epidemicus for the COVID-19 pandemic. Homeopathy 2020; 109: 271-272
• 14 Prajapati S. Isopathic remedy prepared from convalescent plasma as a therapeutic option for COVID-19?. Homeopathy 2020; 109: 184-185
• 15 Basu N, Das BC, Tandon S. Interim management of COVID-19 by repurposed homeopathic medicines. Homeopathy 2020; 109: 182-183
• 16 Rutten L, Merizalde B, van Haselen RA. et al. Collecting clinical experience of homeopathic support in COVID-19–10. May 25, 2020; LMHI newsletter, 10th Issue. Available at: https://www.lmhi.org/Home/Covid19
• 17 Chakraborty PS, Lamba CD, Nayak D. et al. Effect of individualized homoeopathic treatment in influenza like illness: a multicenter, single blind, randomized, placebo controlled study. Indian J Res Homoeopathy 2013; 7: 22-30
• 18 Mathie RT, Baitson ES, Frye J, Nayak C, Manchanda RK, Fisher P. Homeopathic treatment of patients with influenza-like illness during the 2009 A/H1N1 influenza pandemic in India. Homeopathy 2013; 102: 187-192
• 19 Allen TF. The Encyclopedia of Pure Materia Medica. New Delhi: B. Jain Publishers Pvt. Ltd.; 1982. , vol. II:249–303; vol. IV:385–403; vol. VII:366–464
• 20 Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332
• 21 Dean ME, Coulter MK, Fisher P, Jobst K, Walach H. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. Homeopathy 2007; 96: 42-45
• 22 Govt. of West Bengal: Dept. of Health and Family Welfare. Corona Bulletin. Accessed May 22, 2021 at: https://www.wbhealth.gov.in/pages/corona/bulletin